ArticleInternational journal of nanomedicine2011
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.
Article in International journal of nanomedicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Histochemistry for Molecular Imaging in Nanomedicine.International journal of molecular sciences · 2024Review
- Effect of drug-to-lipid ratio on nanodisc-based tenofovir drug delivery to the brain for HIV-1 infection.Nanomedicine (London, England) · 2022Article
- Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles.Nature communications · 2021Article
- Author Correction: Prolonged-acting, Multi-targeting Gallium Nanoparticles Potently Inhibit Growth of Both HIV and Mycobacteria in Co-Infected Human Macrophages.Scientific reports · 2021Article
- Synthesis and Characterization of Long-Acting Darunavir Prodrugs.Molecular pharmaceutics · 2020Article
- A long acting nanoformulated lamivudine ProTide.Biomaterials · 2019Article
- Synthesis of a long acting nanoformulated emtricitabine ProTide.Biomaterials · 2019Article
- The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture.Trends in microbiology · 2019Review
- Modulating cellular autophagy for controlled antiretroviral drug release.Nanomedicine (London, England) · 2018Article
- Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice.The Journal of pharmacology and experimental therapeutics · 2018Article
- Creation of a long-acting nanoformulated dolutegravir.Nature communications · 2018Article
- Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.Biomaterials · 2018Article
- Long-acting slow effective release antiretroviral therapy.Expert opinion on drug delivery · 2017Review
- Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.The Journal of clinical investigation · 2017Article
- Development and characterization of a long-acting nanoformulated abacavir prodrug.Nanomedicine (London, England) · 2016Article
- Poly(lactic-co-glycolic) Acid-Chitosan Dual Loaded Nanoparticles for Antiretroviral Nanoformulations.Journal of drug delivery · 2016Article
- Prolonged-acting, multi-targeting gallium nanoparticles potently inhibit growth of both HIV and mycobacteria in co-infected human macrophages.Scientific reports · 2015Article
- Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.Biomaterials · 2015Article
- Article
- Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.Antimicrobial agents and chemotherapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Nanoformulations of crystalline indinavir, ritonavir, atazanavir, and efavirenz were manufactured by wet milling, homogenization or sonication with a variety of excipients. The chemical, biological, immune, virological, and toxicological properties of these formulations were compared using an established monocyte-derived macrophage scoring indicator system. Measurements of drug uptake, retention, release, and antiretroviral activity demonstrated differences amongst preparation methods. Interestingly, for drug cell targeting and antiretroviral responses the most significant difference among the particles was the drug itself. We posit that the choice of drug and formulation composition may ultimately affect clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.